Pleas	se type a plus sign (+) inside this box +	Attorney Docket P1979R1 PATENT
U	11 925 065 US: Express Mail Number Nove Move	ファンジンス mber 28, 2003: Date of Deposit
	IN THE UNITED STATES PATENT AND	TRADEMARK OFFICE O
Comm P.O. B	op PATENT APPLICATION issioner for Patents ox 1450 dria, VA 22313-1450	22581 U.S.F 10/71931
	NON-PROVISIONAL APPLICATION TRANSMI	TTAL UNDER 37 CFR 1.53(b)
Transn	nitted herewith for filing is a non-provisional patent appl	ication:
Invento	or(s) (or Application "Identifier"):	
	Paul G. Brunetta, San Francisco, California Mark X. Sliwkowski , San Carlos, California	
Title:	THERAPY OF NON-MALIGNANT DISEAS ANTIBODIES	ES OR DISORDERS WITH ANTI-ERBB2
1.	Type of Application	
[]	This application is for an original, non-provisional app	lication.
[X]	This is a non-provisional application claiming pr 60/428,027 , filed November 21, 2002 , the eincorporated by reference.	iority to provisional application no. entire disclosure of which is hereby
[]	This is a [] continuation-in-part [] continuation priority to application Serial Number, filed, the incorporated by reference.	[] divisional application claiming entire disclosure of which is hereby
2.	Papers Enclosed Which Are Required For Filing D (Non-provisional) 56 pages of specification 5 pages of claims 1 page(s) of abstract 12 sheet(s) of drawings [X] formal [] informal	ate Under 37 CFR 1.53(b)

P1979R1 Page 2 of 4

3.	Declaration or Oath
	(for new and CIP applications; also for Cont./Div. where inventor(s) are being added) X An executed declaration of the inventor(s) [] is enclosed [X] will follow.
	(for Cont./Div. where inventorship is the same or inventor(s) being deleted) A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).
	(for Cont./Div. where inventor(s) being deleted) A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).
4.	Assignment
	(for new and CIP applications) X An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [X] will follow.
	(for cont./div.) The prior application is assigned of record to Genentech, Inc.
5.	Amendments (for continuation and divisional applications)
	Cancel in this application original claims _ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)

A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

		CLAIN	IS FOR FEE (CALCULATION	
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$770.00
Total Claims	46	- 20 =	26	X \$18.00	\$468.00
Independent Claims	6	- 3=	3	X \$86.00	\$258.00
Multiple dependent claim(s), if any		n(s), if any	+ \$290.00	\$0.00	
				Filing Fee Calculation	\$1,496.00

7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$1,496.00. A duplicate copy of this transmittal is enclosed.

8. Authorization to Charge Additional Fees

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this transmittal is enclosed.**

9.	Additio	nal Papers	Enclosed
J	Auuluu	illai Paveis	Elicioseu

IJ	Information Disclosure Statement (37 CFH §1.98) W/P10-1449 and citations
	Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing,
	and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino
	acid sequence.

[] A new Power of Attorney or authorization of agent.

10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)

[This item **must** be completed and the necessary papers filed in the prior application if the period set in the prior application has run]

 A petition, fee and/or response has been filed to extend the term in the pending prior application until
 A copy of the petition for extension of time in the <i>prior</i> application is attached.

11. Correspondence Address:

X Address all future communications to:

Attn: Wendy M. Lee Customer No: 09157

Rum

21 Date: November 26, 2003 Respectfully submitted, GENENTECH, INC.

Wendy M. Lee Reg. No. 40,378

Telephone No. (650) 225-1994

CUSTOMER NO: 09157